| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 0.2 |
| Profit before tax | -52.2 | -35.3 |
| Net income | -35.6 | -16.5 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -19.8% |
|---|
10-Q filed with the SEC, NASDAQ: PROK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Prokidney Corp.: key numbers
- Share price
- $1.04Close, Nov 16
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Prokidney Corp.
All →Prokidney Financial Results
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
- Term
- Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Bruce Culleton, M.D., CEO of ProKidney
Prokidney Investor Presentation
ProKidney Corp. has updated its corporate investor presentation for November 2026, which management intends to use for interactions with investors and analysts. The filing also discloses that the company held $141.9 million in cash, cash equivalents, and marketable securities as of September 30, 2026, with a projected cash runway into mid-2027.
Prokidney Capital Raise
ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) offering program. Under the agreement, the company may offer and sell shares of its Class A common stock with a maximum aggregate offering price of up to $200 million. Jefferies will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds from any shares sold.
- Counterparty
- Jefferies LLC